Free Trial
NASDAQ:CNTA

Centessa Pharmaceuticals Q1 2025 Earnings Report

Centessa Pharmaceuticals logo
$11.94 0.00 (0.00%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$11.94 0.00 (0.00%)
As of 04/15/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

Centessa Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Centessa Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Remove Ads

Centessa Pharmaceuticals Earnings Headlines

Morgan Stanley Remains a Buy on Centessa Pharmaceuticals (CNTA)
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Centessa reports Q4 EPS (84c), consensus (35c)
See More Centessa Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA), a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

View Centessa Pharmaceuticals Profile

More Earnings Resources from MarketBeat